Natera Soars 5% on FDA Approval and Performance Momentum, Market Cap Increases by 2.5 Trillion Won

On April 20, Natera Inc. (NASDAQ: NTRA) closed at $206.50—a 5.34% increase—bringing its market capitalization to approximately $29.5 billion (about KRW 45 trillion). In a single day, its market cap rose by roughly $1.67 billion (KRW 2.5 trillion). Trading volume surged to 1,216,281 shares, well above the company’s average.

Earlier this month, Natera reported first-quarter revenue of $696.6 million, a 39% year-over-year increase, driven by record test volumes in both its women’s health and oncology businesses, underscoring its strong growth trajectory. Investor enthusiasm accelerated further after the U.S. Food and Drug Administration approved Natera’s Signatera™ CDx minimal residual disease (MRD) blood test as the first blood-based companion diagnostic for guiding Tecentriq® (atezolizumab) adjuvant therapy in patients with muscle-invasive bladder cancer.

Natera is a diagnostics company that leverages cell-free DNA–based genetic testing to commercialize noninvasive blood tests across oncology, prenatal/maternal health, and organ transplantation. Its flagship products include Signatera for tracking cancer MRD, Panorama™ for noninvasive prenatal screening, and Prospera™ for monitoring kidney transplant rejection.